NEW YORK AND LONDON
Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology Scientific Advisory Board (SAB).
AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE
Footer
Follow Us
